Background--Vitamin K antagonist (VKA) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy. We sought to identify factors associated with TTR in a large, international clinical trial.
B
oth the efficacy and safety of warfarin anticoagulation in patients with atrial fibrillation (AF) are strongly dependent on the intensity of anticoagulation measured as the international normalized ratio (INR). The risk of ischemic stroke increases with INR levels <1.8, and the risk of intracranial hemorrhage increases sharply at INR levels >3.5.
1
These findings support the standard "therapeutic" INR range of 2.0 to 3.0 for atrial fibrillation. [2] [3] [4] A commonly used summary of the quality of warfarin anticoagulation is the linearly interpolated percent time in the therapeutic range (TTR). [5] [6] [7] While many patient-and system-level variables have been demonstrated to affect the INR, and there have been analyses of variation of average TTR at the institutional or geographic level, 8, 9 there are relatively few large studies assessing the impact of patient features on TTR at the level of the individual patient. 10 In the current study, we explored individual and regional determinants of TTR among patients randomly allocated to warfarin in the global ROCKET AF (Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) double-blind trial of rivaroxaban versus adjusted-dose warfarin in patients with atrial fibrillation.
11,12

Methods
The design, conduct, and main results of the ROCKET AF trial have been presented previously. 11, 12 In brief, rivaroxaban (20 mg daily; 15 mg daily in patients with creatinine clearance of 30 to 49 mL/min) was compared with adjusted-dose warfarin (INR point target of 2.5, INR range 2.0 to 3.0) for the prevention of stroke or systemic embolism. Patients with electrocardiographically documented nonvalvular atrial fibrillation at moderate to high risk of stroke were recruited at 1178 participating sites in 45 countries. Elevated risk was indicated by a history of stroke, transient ischemic attack (TIA), or systemic embolism or ≥2 of the following: heart failure or left ventricular ejection fraction ≤35%, hypertension, age ≥75 years, or diabetes mellitus (CHADS 2 score ≥2). 13 The proportion of patients without prior ischemic stroke, TIA, or systemic embolism and ≤2 risk factors was limited to 10% of the cohort by region; the remainder required either prior thromboembolism or ≥3 risk factors. Investigators were chosen on the basis of performance in clinical trials and access to large clinical practices that included patients with atrial fibrillation. We do not have comprehensive information on recruiting physicians' specialty status. Warfarin dosing was managed by local physicians based on INR values generated by a standard point-of-care device (HemoSense, San Jose, CA). While physicians were reminded about the INR target of the trial and the need for monthly INR tests even when patients' anticoagulation status was stable, 14 the study did not provide specific treatment algorithms for anticoagulation management. Patients with <6 weeks of exposure to vitamin K antagonist (VKA) medication immediately before entry into the trial were considered VKA naïve.
Statistical Analysis
For the current analyses, patients were included if they had been assigned to warfarin in the ROCKET AF trial and took Only variable values at entry to the study were used. Multivariable models were developed both with and without a random effect for center; we report only the results for the models without a random effect for center, because both modeling approaches produced highly similar results. Regional and country mean i-TTRs were unweighted averages of i-TTR values for all individuals within the given region or country, respectively. The relationship between geographic region and i-TTR was further characterized using linear regression models with region as the only predictor within subgroups defined by prior VKA experience, both for i-TTR and for i-TTR excluding the first 90 days of warfarin therapy. For the current analysis, we grouped the countries involved in the ROCKET AF trial into the following regions: East Asia (China, Hong Kong, Korea, Malaysia, Philippines, Singapore, Thailand, and Taiwan); India; Eastern Europe (Bulgaria, Czech Republic, Greece, Hungary, Lithuania, Poland, Romania, Russia, Turkey, and Ukraine); Western Europe and similar (Western Europe/similar: Australia, Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, Great Britain, Israel, Italy, Netherlands, Norway, New Zealand, and Sweden); South Africa; Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, and Venezuela); and Canada/United States. These regional groupings were modified from those used in the primary trial report to provide more cultural and ethnic homogeneity. 12 Analyses done with the original regional groupings reproduced the same patterns of regional effect on average i-TTR although the overall R 2 values for the multivariable models were modestly reduced (data not shown). We did not include terms for both region and race in the same multivariable models because the 2 were almost completely collinear. We summarize stroke risk using the CHADS 2 score. 13 Statistical significance of differences in the width of distributions of INR values across regions was assessed using the Miller jackknife technique. 16 
Human Subjects
All individuals enrolled in the study gave informed consent. All appropriate national regulatory authorities and ethics committees at participating centers approved the study. An international executive committee designed the study and takes responsibility for the accuracy and completeness of all analyses.
Results
Baseline Patient Features
The ROCKET AF trial recruited atrial fibrillation patients at high risk for ischemic stroke. In the subpopulation (n=6983) included in the current analysis, the mean age was 71 years (median 73 years), 61% were male, 52% had had a prior stroke or TIA, and the mean CHADS 2 stroke risk score was 3.3. A total of 83% were white, 12% were Asian, and there was a small representation of other racial/ethnic groups. Enrolled patients came from a broad set of geographic regions: 38% from Eastern Europe, 19% from Canada/United States, 16% from Western Europe/similar, 13% from Latin America, and 10% from East Asia ( Table 1) . Thirty-seven percent of patients were VKA naïve. Of the 4387 patients taking VKAs before entry into the trial, 1334 were not taking warfarin ( Table 2) . Detailed features of patients participating in the ROCKET AF trial, stratified by geographic region, are presented in Table  S1 . Tables 1 and 2 ). Younger patients, female patients, those with heart failure, and patients with higher CHADS 2 scores had lower mean i-TTR levels. Asian patients had a mean i-TTR a full 8% lower than did white patients. Patients who reported light to moderate alcohol consumption had higher i-TTR levels than did those who were alcohol abstinent. Prior experience with warfarin had a notably strong association with i-TTR. Warfarinexperienced patients had a mean i-TTR of 61.1% compared with a mean of 47.4% for VKA-naïve patients. Patients who had previously taken non-warfarin VKAs had a mean i-TTR of 56.9%. Multiple other medications taken at entry into the study were statistically associated with i-TTR. During followup, 2287 patients had ≥1 hospitalizations. There was no decrease in mean i-TTR among these hospitalized patients compared with those avoiding hospitalization during the trial (data not shown). 
Univariable Associations With i-TTR
Association of Geographic Region and Mean i-TTR
There was remarkable variation in mean i-TTR across geographic regions, ranging from 36% in the small group of patients treated in India to 50% for patients treated in Eastern Europe and East Asia to 63% and 64%, respectively, for patients treated in Western Europe/similar and Canada/ United States ( Figure 1a ). Across regions, there were marked differences in the proportion of patients naïve to VKAs, ranging from 9.7% of patients in Canada/United States to 53% in Eastern Europe. In Canada/United States, East Asia, and There were no missing data for this Table. i-TTR indicates individual patient-level time in therapeutic range; VKA, vitamin K antagonist; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
South Africa, the predominant VKA used before the trial was warfarin. But, in the remaining regions, many patients who were VKA experienced were still warfarin naïve (Table 3) . Nonetheless, the qualitative regional patterns of i-TTR across regions persisted after stratification by patients' experience with VKAs, although the absolute differences in mean TTR were modestly reduced. Patients treated in Canada/United States and Western Europe/similar still had the highest TTRs, whether patients were experienced with warfarin or completely VKA naïve. The point estimates were modestly higher for Western Europe/similar versus Canada/United States in these stratified analyses (Table 3) . Country-level patterns of mean i-TTR stratified by warfarin experience at baseline are presented in Figure 1b through 1d. By 90 days, patients newly started on warfarin should have achieved a relatively stable dose. Analyses excluding the first 90 days of follow-up resulted in improved regional mean i-TTRs, particularly in regions with a high proportion of patients naïve to warfarin. Despite these changes, the regional- (Table 4) and country-level (Figure 1e ) differences persisted. When we further stratified these analyses starting at 90 days by patients' previous exposure to warfarin and VKAs, the regional TTR patterns were preserved (data not shown).
Multivariable Associations With i-TTR
In multiple linear regression models of mean i-TTR, many features remained statistically significant (Table 5) . Particularly strong effects were seen for patients who were VKA naïve (À9.1%, compared with warfarin experienced), women (À9.3%), patients with heart failure (À3.2%), patients with chronic obstructive pulmonary disease (À2.9%), patient using amiodarone at study entry (À3.6%), and across categories of use of alcohol. Even after adjustment for all other significant features (but leaving out race because of collinearity with region), the effect of geographic region remained remarkable. With Canada/United States patients as the referent group, the mean i-TTR was an absolute 8.6% lower for patients in Eastern Europe, 8.7% lower in East Asia, 4.7% lower in Latin America, and essentially the same for patients treated in Western Europe/similar. The small sample of patients in India had a particularly low average i-TTR. Although there were several strong determinants of mean i-TTR, the overall multivariable model R 2 was only 16%. By percent of variance explained (ie, partial R 2 ), the strongest risk factors were VKA experience (3.7%) and geographic region (4.3%). 
Variation in i-TTR Across Countries
There was substantial variation in i-TTR across the 45 countries in ROCKET AF, ranging from a mean of 36% to 75%. Substitution of individual countries for geographic regions in the multiple linear regression model led to an increase in the overall model R 2 from 16% to 19% (Table 6 ).
Even within regions, there was considerable variability across countries ( Figure 1 ). Of particular interest, the mean TTR was 47% in China and 38% in Taiwan but 66% in Hong Kong and 64% in Singapore. Ninety-nine percent of the patients in all 4 of these regions were identified as being of Asian race. When we substituted patient's race for patient's region in the multivariable model, the overall model R 2 deteriorated to 12.8% (Table 7) .
Distribution of INR Values and Management of Test Results
Geographic regional variation in mean i-TTR levels was largely due to time at INR <2.0 ( Figure 2 , Table 8 Figure 3 displays the distribution of mean intertest intervals as a function of initial INR test result. There is an inverted "U" pattern seen in all regions but inter-test intervals were shortest in regions with the highest TTRs, regardless of initial test result.
Discussion
The linearly interpolated TTR has become a widely accepted measure of the quality of anticoagulation management. 7 In the ROCKET AF trial, the mean i-TTR for patients assigned to warfarin was 55%, lower than that reported for other recent trials of novel anticoagulants, [17] [18] [19] with a wide range of i-TTR values. The ROCKET AF trial enrolled patients at particularly high risk of stroke. One of these stroke risk factors, heart failure, was associated with an adjusted 3% decrease in average i-TTR. However, other standard stroke risk factors in AF (ie, prior stroke/TIA, hypertension, and diabetes) had only modest, if any, univariate effects on i-TTR and none was selected as a significant predictor of i-TTR in our multivariable model. The 2 strongest determinants of i-TTR (by partial R 2 )
were not patient comorbidities but rather pretrial experience with warfarin and geographic site. Patients who were taking i-TTR indicates individual patient-level time in therapeutic range; VKA, vitamin K antagonist; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; BP, blood pressure; BMI, body mass index. *For the multivariable model results reported in Table 4a through 4c, n=6961 with 22 subjects omitted because of missing covariate values. 
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Continued warfarin before entry into the trial had an adjusted absolute 9% higher mean i-TTR than those who were VKA naïve. Interregional mean i-TTR varied by as much as 21%, even after accounting for patient clinical features and experience with warfarin. Excluding the small number of patients treated in India, interregional differences in mean i-TTR still spanned an absolute 8.7%. Excluding the first 90 days of warfarin treatment, to allow warfarin-naïve patients to become warfarin-experienced, still resulted in large interregional differences in mean TTR. When country was included in the model instead 2.0 to 3.0. The fact that the mean TTR for patients treated in Hong Kong and Singapore was much higher than the mean TTR in the remaining countries in East Asia indicates that medical care practices and not race determine anticoagulation control in this region. 21 14 This is in contrast to usual clinical care where the distribution of test intervals is broader, adding uncertainty to the calculation of TTR. 23 Our study has limitations. As always, our trial-based results may not generalize completely to usual clinical care. Our regional findings reflect the care provided by a limited set of investigators in any geographic region. As such, we cannot claim that our findings are clearly representative of warfarin management in participating countries. However, it is notable that the regional pattern of our results is similar to those reported by the ACTIVE W trial for the countries where both trials recruited patients. 8 In particular, in both the ROCKET AF and ACTIVE W trials the country with the highest i-TTR was Sweden and a recent survey of anticoagulation in clinical care in Sweden reported a mean i-TTR of 74%, nearly identical to the value of 75% observed in the ROCKET AF trial. 24 We cannot account for the resource constraints or cultural norms underlying different regional practices in managing warfarin. The widely used Rosendaal measurement of i-TTR uses linear interpolation to impute daily INR values. Other imputation approaches might reduce interregional differences in i-TTR. Ultimately, while i-TTR makes sense as a measure of the quality of warfarin management, its quantitative relationship to the net benefit of warfarin therapy is still uncertain.
In conclusion, we found that patient clinical features, such as heart failure, were significant but modest determinants of i-TTR. Further, we were able to quantify the reduced control of warfarin anticoagulation faced by new users of the drug. However, our most notable finding was the striking influence of geographic region, presumably reflecting different levels of aggressiveness in achieving the INR point target of 2.5, different support systems to manage warfarin, and different regional barriers to frequent INR testing and warfarin dose changes. Such geographic variation in medical practice has become a truism of health care epidemiology. 25, 26 While our understanding of the determinants of i-TTR remains incomplete, it is clear that the providers of care, and the systems within which they work, have a profound effect on the quality of anticoagulation.
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